Barclays initiated coverage on Revolution Medicines with a new price target

7/12/24 7:33:26 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Barclays initiated coverage of Revolution Medicines with a rating of Overweight and set a new price target of $52.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RVMD

Date	Price Target	Rating	Analyst
7/16/2024	$46.00 → $62.00	Buy	Needham
7/12/2024	$52.00	Overweight	Barclays
7/8/2024	$63.00	Buy	Jefferies
4/12/2024	$36.00 → $46.00	Buy	Needham
4/10/2024	$36.00 → $48.00	Outperform → Strong Buy	Raymond James
3/11/2024	$43.00	Overweight	Piper Sandler
1/5/2024	$31.00 → $34.00	Neutral → Buy	BofA Securities
1/4/2024	$41.00	Outperform	Wedbush